Pembrolizumab with or without olaparib following pembrolizumab with chemoradiation therapy for previously untreated, advanced, stage III non-small-cell lung cancer

Pembrolizumab with or without olaparib following pembrolizumab with chemoradiation therapy is currently in development for treatment of adults with unresectable, locally advanced, stage III non-small-cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer. Advanced cancer often refers to cancer that cannot be cured. Stage III NSCLC is considered “locally advanced,” meaning that it has spread regionally, in the area near the original tumour. The main risk factor for lung cancer is smoking. Some symptoms of lung cancer include a persistent cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness. Lung cancer remains the leading cause of cancer deaths, and there is need for more treatment options to prolong survival and preserve quality of life.